2007: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's: Clinical Aspects and Therapeutics I

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's: Clinical Aspects and Therapeutics I

1

Similar Outcome and Organ Involvement Patter of Patients with Juvenile and Young Adult Onset Systemic Sclerosis. Data from the Eustar Database

2

Skin Thickness Progression Rate in Systemic Sclerosis with Diffuse Cutaneous Involvement: A Predictor of Outcome

3

The Prognostic Value of Renal Biopsy in Scleroderma Renal Crisis

4

Obstetric Hospitalizations in Women with Systemic Sclerosis and Primary Pulmonary Hypertension

5

Prevalence and Clinical Correlates of Symptoms of Depression in Patients with Systemic Sclerosis

6

Risk Factors For Mortality In Patients With Systemic Sclerosis And Interstitial Lung Disease

7

Chronic Articular Involvement In Systemic Sclerosis

8

Intraspinal and Paraspinal Calcinosis Associated with Systemic Sclerosis

9

Hospital-Based Management of Severe Digital Vasculopathy in Systemic Sclerosis

10

Predictive Value of Nailfold Capillaroscopic Findings in Patients with Raynaud Phenomenon

11

Diagnostic Validity in Detecting Different Capillaroscopic Patterns by Qualitative versus Quantitative Scoring Methods

12

Utility and Reliability of Different Capillaroscopic Measures for the Identification of Secondary Raynaud’s Phenomenon

13

Cardiac Involvement in Systemic Sclerosis: The Strongest Predictive Factor of Prognosis in Patients with Scleroderma

14

Sub-Maximal Exercise Testing in the Prospective Assessment of Interstitial Lung Disease (ILD) Secondary to Systemic Sclerosis (SSc): Correlations with Objective and Subjective Measures of Parenchymal Lung Disease

15

Gastric Antral Vascular Ectasia in Systemic Sclerosis

16

Brain Natriuretic Peptide and Uric Acid as Predictors of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis

17

Lower Gastrointestinal Symptoms and Quality of Life in Patients with Systemic Sclerosis. A Population-Based Study

18

Characteristics of Patients with Early Systemic Sclerosis and Severe Gastrointestinal Tract Involvement

19

Predicting Pulmonary Artery Hypertension in Patients with Systemic Sclerosis.

20

Fulminant Scleroderma as an Early Cause of Death in Patients with Systemic Sclerosis

21

Physician and Patient Assessment of Disease Severity in Systemic Sclerosis (SSc)

22

Ambulatory Raynaud’s Monitor: A Novel Measurement Device to Assess Raynaud’s Phenomenon in an Ambulatory Setting

23

Radiological and Functional Lung Indices Worsening in Scleroderma Patients: Relationship with Alveolitis and Low Respiratory Tract Infections

24

Sparing of the Thumb in Raynaud’s Phenomenon

25

Is Statin Use Protective Against Development of Systemic Sclerosis? A Retrospective Case Controlled Study

26

Safety and Tolerability of MQX-503, a Novel Investigational Topical Formulation of Nitroglycerin for the Treatment of Raynaud’s Phenomenon

27

Promising Effects of Mycophenolate Mofetil on Autoimmune Related Pulmonary Fibrosis

28

Phenotypical and Functional Characteristics of in vitro Expanded Bone Marrow Mesenchymal Stem Cells from Systemic Sclerosis Patients

29

Are Scleroderma Patients Less Microchimeric after Autologous Stem Cell Transplantation?

30

EULAR/EUSTAR Recommendations for the Treatment of Systemic Sclerosis (SSc)

31

Evolution of Fibrosing Alveolitis Associated with Systemic Sclerosis after Autologous Bone Marrow Transplantation

32

Imatinib Mesylate Treatment Improves Skin Changes of Nephrogenic Systemic Fibrosis

See more of: ACR Abstract Submission Poster Sessions

<< Previous Session Level | Next Session Level >>